ArticleCalcified tissue international2026
Parathyroid Hormone Related Peptide (PTHrP) Revisited: A Comparison of Levels in Malignant and Non-malignant Conditions.
Article in Calcified tissue international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated parathyroid hormone-related peptide (PTHrP) levels are often presumed to indicate malignancy-associated hypercalcemia, yet PTHrP may be elevated in nonmalignant conditions. We compared PTHrP levels in patients with known malignancies with patients with elevations of PTHrP who had defined nonmalignant diagnoses to determine which levels of PTHrP were more indicative of malignancy. A retrospective review of electronic medical records in a large midwestern hospital system was conducted using search terms hypercalcemia with elevated PTHrP (> 2.3 pmol/L (men) and > 3.4 pmol/L (women). Binary logistic regression analyses assessed the positive predictive value (PPV, probability) of cancer. Among 236 patients with hypercalcemia and elevated PTHrP, 58 had known cancer. The others had defined nonmalignant diagnoses including primary hyperparathyroidism (n = 87), absorptive hypercalcemia (n = 28), and "other" causes (n = 63). PTHrP was highest in the cancer group (PTHrP = 36.9, 95% CI 19.8, 53.9 pmol/L, p < 0.001), however, overlap occurred. Binary logistic regression analyses showed a positive association of PTHrP levels (p < 0.001), while PTH levels were negatively associated (p < 0.001) with the presence of cancer. When analyzed together, PTH on PTHrP had independent effects (p < 0.001). At PTH ≥ 30 pg/mL, the PPV of cancer was < 5% when PTHrP < 7.0 pmol/L and < 10% at a PTHrP < 9.0 pmol/L. In the evaluation of hypercalcemia with elevated PTHrP, simultaneous levels of PTH measurements improve estimation of cancer probability. Mild PTHrP elevations with PTH > 30 pg/mL are more consistent with nonmalignant diagnoses, although higher PTHrP levels may still warrant evaluation for occult malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.